Navigation Links
Mount Sinai's Arvin Dar, Ph.D., receives NIH New Innovator Award for drug development
Date:11/15/2013

Arvin Dar, PhD, structural and chemical biologist in oncological sciences at the Icahn School of Medicine at Mount Sinai, is one of 41 national recipients of the prestigious National Institutes of Health (NIH) Director's New Innovator Awards for High-Risk, High Reward Research. The award will support Dar's research into Ras-dependent cancers, specifically investigating how to combat mutations in Ras, a protein implicated in at least one of every five cancers.

Even though Ras mutations have long been known as critical drivers of cancer, metastasis, and resistance to chemotherapy, drug development in this area has been dissappointing. It turns out that the structural biology underlying Ras mutations is extremely complex.

Dr. Dar, along with other researchers at the Icahn School of Medicine at Mount Sinai and the University of California San Francisco have been instrumental in advancing this research.

Dr. Dar's laboratory has been investigating new targets or strategies that show promise in interrupting the Ras pathway. The work is highly interdisciplinary, incorporating methods from synthetic organic chemistry, mass spectrometry, informatics, biochemistry, and model organism genetics. The eventual goal is to produce new classes of small molecule drugs that impede cancers.

"NIH is excited to support visionary investigators," said NIH Director Francis S. Collins, MD, PhD. This research has "the potential to transform scientific fields and accelerate the translation of scientific research into improved health."

The NIH Common Fund, in partnership with other NIH Institutes, are key backers of the NIH Director's New Innovators Fund. These programs are designed to overcome major research barriers, specifically catalyzing disease-specific research.

In accepting the award, Dr. Dar said: "It is truly an honor to be included in this year's recipients as it is a highly competitive funding mechanism. I have benefited greatly from support and mentorship of Mount Sinai faculty, including Stuart Aaronson and Ross Cagan, as well as my postdoctoral advisor, Kevan Shokat, at the University of California San Francisco. My previous work with them has led to a compound that is currently progressing towards a human clinical trial, and this new funding will allow us to explore new avenues in drug therapy."

Thirty years ago, Mount Sinai researchers played a pivotal role in first discovering Ras mutations, and their relationship to cancer biology. Stuart Aaronson, PhD, and Prem Reddy, PhD, made significant inroads in uncovering Ras mutations.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
2. Lipitor Lawsuits Continue to Mount, as Bernstein Liebhard LLP Notes Filing of New Claim Alleging an Association Between Lipitor and Diabetes
3. Mount Sinai's Novel Gene Therapy Works to Reverse Heart Failure
4. Mount Sinai Makes Innovation a Team Effort At Its Second Annual Sinainnovations Conference, November 18-19, 2013 In NYC
5. Mount Sinai Dermatology Department in NY Opens New Practice in Chinatown
6. Pradaxa Lawsuits Continue to Mount, With Filing of New Pradaxa Wrongful Death Claim in Pennsylvania by Wright & Schulte LLC
7. National Association of Professional Women Announces Elizabeth C. Abel, M.S.W., Project Director, CAPP of City of Mount Vernon-Youth Bureau, as VIP Woman of the Year
8. Newcastle, Oklahoma High School Provides Football Team with Brain Sentry Impact Sensor, Helmet-Mounted Device Helps ID Players Who Need to be Evaluated for Concussion
9. Peter R. Dottino, MD to Head Division of Gynecologic Oncology at Mount Sinai
10. Mirena Lawsuits Mount, as Bernstein Liebhard LLP Notes More than 400 Mirena IUD Lawsuit Filings in State, Federal Litigations
11. Mount Sinai and the Atlantic Host Working Summit on Big Data in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Dr. Rassouli, cosmetic dentist ... whitening is among the most popular cosmetic procedures in dentistry today, but the cost ... can put them at risk of teeth whitening-related damage. For a limited time, Dr. ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
(Date:2/9/2016)... ... 09, 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers of ... GRIP-DRY is a newly patented product that has solved some of the basic problems golfers ... early morning dew or right after a rain shower, might understand the struggle of placing ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... with BASF Human Nutrition into the Food & Beverage and ... been BASF’s channel partner throughout Canada and USA geographies east of the Rocky ...
(Date:2/8/2016)... Angeles, CA (PRWEB) , ... February 08, 2016 , ... A man who has struggled ... of Freedom Laser Therapy , was determined to find solutions to his problems – ... of Inventors Digest is ready to introduce his breakthrough inventions to the world ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... 2016 first quarter ended December 31, 2015. ... First Quarter Highlights , Revenue of $36.5 million ... 2015 , Domestic Radiation Measurement services revenues increased 2.8% ...
(Date:2/9/2016)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... fourth quarter and full year 2015 financial results ... genome editing," said Edward Lanphier, Sangamo,s president and ... technology leads the therapeutic genome editing field and ... move our ground-breaking genome editing programs through IND ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
Breaking Medicine Technology: